Clinical Trials on Tuberous Sclerosis in Japan

Total 64 results

Nobelpharma

Completed

Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex

Plaque | Tuberous Sclerosis | Angiofibroma | Hypomelanotic Macule

Japan
Nobelpharma

Active, not recruiting

Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC

Tuberous Sclerosis Complex

Japan
Nobelpharma

Completed

Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)

Plaque | Tuberous Sclerosis | Angiofibroma | Hypomelanotic Macule

Japan
Novartis Pharmaceuticals

Completed

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3)

Tuberous Sclerosis Complex-associated Refractory Seizures

United States, Colombia, Belgium, France, Japan, Taiwan, Turkey, Spain, Thailand, Korea, Republic of, Australia, Hungary, United Kingdom, Canada, Norway, Germany, Italy, Russian Federation, Denmark, Argentina, Netherlands, Greece, P... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (EXIST-2)

Lymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)

United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
Novartis Pharmaceuticals

Active, not recruiting

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Tuberous Sclerosis Complex

United States, Spain, Belgium, Taiwan, Turkey, Australia, Korea, Republic of, Thailand, France, Hungary, United Kingdom, Italy, Japan, Canada, Russian Federation, Poland, Mexico, Colombia
National Center of Neurology and Psychiatry, Japan

Completed

Phase II Clinical Trial of OCH-NCNP1

Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Japan
Gunma University

Completed

Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis

Systemic Sclerosis Patients With Digital Ulcers

Japan
Yoshino Neurology Clinic

Unknown

Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Japan
Maruho Co., Ltd.

Active, not recruiting

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

Systemic Sclerosis

Japan
Chiba University

Completed

Open-label Clinical Trial of Lacosamide in ALS

Amyotrophic Lateral Sclerosis

Japan
Takeda

Completed

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Multiple Sclerosis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Japan
Kyowa Kirin Co., Ltd.

Active, not recruiting

A Study of KHK4827 in Patients With Systemic Sclerosis

Systemic Sclerosis

Japan
Kyoto University
Pfizer; Kitasato University; Tokushima University; Tottori University

Recruiting

iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

Amyotrophic Lateral Sclerosis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

Japanese Patients With ALS

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis

Japanese Patients With ALS

Japan
Kyowa Kirin Co., Ltd.

Active, not recruiting

A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

Moderate to Severe Systemic Sclerosis

Japan
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
Tokyo University
Japan Agency for Medical Research and Development; Zenyaku Kogyo Co., Ltd.

Completed

A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis (DesiReS)

Autoimmune Diseases | Collagen Diseases | Scleroderma, Systemic | Lung Fibrosis | Skin Sclerosis

Japan
Mitsubishi Tanabe Pharma Corporation

Recruiting

A Study of MT-0551 in Patients With Systemic Sclerosis

Systemic Sclerosis

Japan
Mayo Clinic
Nagoya University

Completed

Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis

IgG4-related Disease | IgG4-related Sclerosing Cholangitis

United States, Japan
Biogen

Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Japan
Tokyo Medical University

Completed

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)

ALS

Japan
Novartis
Mitsubishi Tanabe Pharma Corporation

Completed

An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis

Japan
Biogen

Active, not recruiting

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Relapsing Multiple Sclerosis

Japan, Russian Federation
University of Tokushima
Eisai Co., Ltd.

Unknown

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS (JETALS)

Amyotrophic Lateral Sclerosis

Japan
Biogen

Completed

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (Tysabri Japan)

Multiple Sclerosis

Japan
Novartis
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

Multiple Sclerosis

Japan
Amgen

Enrolling by invitation

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Korea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
Biogen

Completed

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Korea, Republic of, Taiwan, Czechia, Japan, Poland
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis

Belgium, Spain, Russian Federation, France, Italy, Poland, Sweden, Turkey, Czech Republic, Japan
Novartis Pharmaceuticals

Active, not recruiting

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Relapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple Sclerosis

Japan
EMD Serono
Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd

Terminated

Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) (DreaMS)

Multiple Sclerosis

United States, Belgium, Canada, Czech Republic, Germany, Japan, Poland, Russian Federation, Spain, Ukraine, Greece
Ono Pharma USA Inc

Completed

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)

Multiple Sclerosis

United States, Belgium, Canada, Czech Republic, Germany, Greece, Japan, Poland, Russian Federation, Spain, Ukraine
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States, Canada, Japan, France, Germany, Italy
Corbus Pharmaceuticals Inc.

Terminated

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (RESOLVE-1)

Diffuse Cutaneous Systemic Sclerosis

United States, Switzerland, Korea, Republic of, Australia, Netherlands, Israel, United Kingdom, Germany, Japan, Spain, Poland, Canada
Amgen

Recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Netherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
Eisai Co., Ltd.

Completed

A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Japan
GlaxoSmithKline

Completed

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, France, Australia, Canada, Belgium, Germany, Korea, Republic of, Japan, Netherlands, Italy, United Kingdom
Eisai Co., Ltd.

Completed

A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Japan
Biogen

Recruiting

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

Relapsing Forms of Multiple Sclerosis

China, Japan
Apellis Pharmaceuticals, Inc.

Terminated

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

United States, Netherlands, Spain, Germany, Japan, Australia, France, Poland, Ukraine, Belgium, Czechia, Ireland, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

Secondary Progressive Multiple Sclerosis (SPMS)

Japan
Biogen
Ionis Pharmaceuticals, Inc.

Completed

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C))

Amyotrophic Lateral Sclerosis

United States, Canada, Belgium, France, Australia, Japan, Denmark, Korea, Republic of, United Kingdom, Germany, Italy, Poland
PTC Therapeutics

Active, not recruiting

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS (CARDINALS)

Amyotrophic Lateral Sclerosis

United States, Belgium, Spain, Australia, Germany, Italy, Czechia, France, Netherlands, Japan, Poland, Argentina, Sweden
Sanofi

Recruiting

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS)

Primary Progressive Multiple Sclerosis

Spain, Italy, Turkey, India, Israel, Bulgaria, Mexico, Greece, Portugal, United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Georgia, Germany, Hungary, Japan and more
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more

Clinical Trials on Tuberous Sclerosis in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations